NEW DELHI : The government on Friday said that covid-19 vaccines, especially those based on new technologies like messenger RNA and DNA plasmid, will undergo active surveillance by the regulator even after they receive marketing authorisation to ensure that their safety.“After a complete evaluation process, when we establish safety, only then these (vaccines) get a marketing authorization, and this will be coupled with active surveillance post marketing for monitoring adverse event following immunization," Drug Controller General of India V.G.
Somani said at a webinar.The health ministry, along with Somani, department of biotechnology and NARI, held a webinar on Friday to explain the process of clinical trials, rolling reviews and adverse.